As of June 16, 2025, DiaSys Corp (DYXC) reports a ROE (Return on Equity) of -97.03%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of DiaSys Corp's ROE (Return on Equity)
Over recent years, DiaSys Corp's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2007-06-30 | -97.03% |
| 2006-06-30 | -99.15% |
| 2005-06-30 | -137.63% |
| 2004-06-30 | -169.66% |
| 2003-06-30 | -48.33% |
This slight upward trend highlights how DiaSys Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing DiaSys Corp's ROE (Return on Equity) to Peers
To better understand DiaSys Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| DiaSys Corp (DYXC) | -97.03% |
| Xcorporeal Inc (XCRP) | 1128.52% |
| Echo Therapeutics Inc (ECTE) | 878.82% |
| Bionoid Pharma Inc (BINP) | 541.05% |
| ArtVentive Medical Group Inc (AVTD) | 365.48% |
| Positron Corp (POSC) | 308.72% |
Compared to its competitors, DiaSys Corp's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.